Skip to main content
  • ORION-9 Trial: Inclisiran Safely Lowered LDL-C by 50% in Heterozygous Familial Hypercholesterolemia

    ORION-9, a phase 3 randomized clinical trial, shows that inclisiran effectively reduces low-density lipoprotein cholesterol (LDL-C) by 50% at 18 months in patients with heterozygous familial hypercholesterolemia, according to results presented Monday at the American Heart Association Scientific Sessions 2019 in Philadelphia.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details